Boostrix clinical trials
How each study uses Boostrix is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the Boostrix studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
29 studies that test it; most in 2006 (4)
| Year | Studies |
|---|---|
| 2002 | 1 |
| 2003 | 2 |
| 2006 | 4 |
| 2007 | 4 |
| 2009 | 1 |
| 2010 | 1 |
| 2013 | 2 |
| 2014 | 3 |
| 2015 | 2 |
| 2018 | 2 |
| 2019 | 1 |
| 2022 | 2 |
| 2024 | 1 |
| 2025 | 1 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 24 · Other 5
GlaxoSmithKline (20) · Changchun BCHT Biotechnology Co. (2) · University Hospital, Ghent (1) · Mahidol University (1) · Novartis Vaccines (1) · Sanofi (1) · Canadian Immunization Research Network (1) · Oregon Health and Science University (1)
Often tested with
Tested in the same studies.
Meningococcal Vaccines (3) · Adacel (2) · Hepatitis A Vaccines (2) · Fluarix (1) · Shingrix (1) · 23-valent pneumococcal capsular polysaccharide vaccine (1) · Pneumococcal Vaccines (1) · 13-valent pneumococcal vaccine (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test Boostrix.
- Jan 2027Concurrent Versus Sequential Administration of Tdap and RSV Vaccines in PregnancyPhase 4 · Canadian Immunization Research Network
Studies
Open first, then newest update. How each study uses Boostrix is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 29
- A Phase II Clinical Trial of Absorbed Acellular Pertussis (Two-Component) Diphtheria-Tetanus Combined Vaccine (For Adults and Adolescents)RecruitingPhase 2Changchun BCHT Biotechnology Co.NCT07894055Written as Tdap vaccine
- Concurrent Versus Sequential Administration of Tdap and RSV Vaccines in PregnancyRecruitingPhase 4Canadian Immunization Research NetworkNCT07097012Written as Tdap Vaccine Administration
- A Phase I Clinical Trial of Absorbed Acellular Pertussis (Two-Component) Diphtheria-Tetanus Combined Vaccine (For Adults and Adolescents)Not yet recruitingPhase 1Changchun BCHT Biotechnology Co.NCT07492303Written as Tdap vaccine
- GBS-NN/NN2 (50 µg of Each Fusion Protein [GBS-NN and GBS-NN2] in Combination With 500 µg Aluminum as Alhydrogel®) Given With and Without the Tdap Vaccine in Healthy Non-pregnant Women 18 to 49 Years of AgeWithdrawnPhase 2/3Minervax ApSNCT06494475Written as Tdap vaccine
- The COVID-19 VaccinE Response and Co-Administration in Rheumatology Patients (COVER-CoAd)TerminatedPhase 4Oregon Health and Science UniversityNCT05543642Written as Diphtheria, pertussis, and tetanus booster vaccine
- A Study of a Vaccine Against Respiratory Syncytial Virus (RSV) When Given Alone and Together With a Vaccine Against Diphtheria, Pertussis and Tetanus (Tdap) Viruses Followed by a 2nd Dose of the RSV Vaccine to Healthy Non-Pregnant WomenCompletedPhase 2GlaxoSmithKlineNCT04138056Written as Boostrix-US
- A Study to Evaluate the Safety and Immune Response to an Unadjuvanted RSV Maternal Vaccine in Healthy Non-pregnant Females From 9 to 49 Years of AgeCompletedPhase 3GlaxoSmithKlineNCT05169905Written as dTpa vaccine
- Placebo Controlled Study to Generate Data Characterising Safety Parameters and Immune ResponsesCompletedPhase 4University Hospital, GhentNCT02555540Written as Boostrix
- Evaluation of Immunogenicity, Safety and Reactogenicity of GSK Biologicals' Boostrix Vaccine Administered as a Booster Dose in Healthy Russian SubjectsCompletedPhase 3GlaxoSmithKlineNCT03311659Written as Boostrix
- Seroprevalence of Bordetella Pertussis Antibodies and Anti-pertussis Antibody Response After a Single Dose of Tdap in Pregnant Thai WomenCompletedEarly Phase 1Mahidol UniversityNCT03498300Written as Tdap vaccine
- Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Boostrix™ Vaccine in Pregnant WomenCompletedPhase 4GlaxoSmithKlineNCT02377349Written as Boostrix™
- Immunogenicity & Reactogenicity of Boostrix 10 Years After Previous Booster Vaccination in Study NCT01267058CompletedPhase 4GlaxoSmithKlineNCT00548171Written as Boostrix™
- Evaluation of GlaxoSmithKline Biologicals' Boostrix® Vaccine in Comparison With Decavac™ Vaccine.CompletedPhase 3GlaxoSmithKlineNCT00835237Written as Boostrix®
- Immunogenicity, Safety of GSKs Tdap Vaccine Boostrix When Coadministered With GSKs Influenza Vaccine Fluarix in AdultsCompletedPhase 3GlaxoSmithKlineNCT00385255Written as Boostrix®
- Evaluation of Boostrix™10 Years After Previous Booster VaccinationCompletedPhase 4GlaxoSmithKlineNCT01147900Written as Boostrix™
- US-licensed Combined Vaccine Against Tetanus & Diphtheria, Given With US-licensed Vaccine Against Meningococcal DiseaseCompletedPhase 4GlaxoSmithKlineNCT00282295Written as Boostrix®
- Safety and Immunogenicity of GSK's Tdap Vaccine (Boostrix) in Adults Aged 19 to 64 YearsCompletedPhase 3GlaxoSmithKlineNCT00346073Written as Boostrix™
- Safety of a Booster Dose of GlaxoSmithKline (GSK) Biologicals' Boostrix™ Vaccine in Healthy Vietnamese ChildrenCompletedPhase 3GlaxoSmithKlineNCT01988857Written as Boostrix™
- Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Boostrix™ Vaccine in Previously Boosted Young AdultsCompletedPhase 3GlaxoSmithKlineNCT01738477Written as Boostrix
- Study to Assess the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine (GSK1437173A) When Co-administered With GSK Biologicals' Diphtheria, Tetanus and Pertussis Vaccine (Boostrix®) in Adults Aged 50 Years and OlderCompletedPhase 3GlaxoSmithKlineNCT02052596Written as Boostrix
See all 29 studies that test Boostrix →
Given beside what is tested · 7 — Boostrix is usual care or a partner of the new treatment
- A Study to Investigate Vaccine Responses in Subcutaneous Amlitelimab Treated Atopic Dermatitis Participants Aged 18 Years and Older Compared With PlaceboCompletedPhase 2SanofiNCT06015308Written as Tdap vaccine
- Vaccine Responses in Tralokinumab-Treated Atopic Dermatitis - ECZTRA 5 (ECZema TRAlokinumab Trial No. 5)CompletedPhase 2LEO PharmaNCT03562377Written as Tdap vaccine
- Persistence Study of GSK Biologicals' Tdap Vaccine 1, 3, 5 and 9 Years Following Administration as an Initial Single Dose in Healthy Young Adults and to Evaluate the Immunogenicity and Safety of Boostrix as a Second Dose of Tdap, When Administered at Year 9CompletedPhase 3GlaxoSmithKlineNCT00489970Written as Boostrix
- Viaskin Pertussis Vaccine TrialCompletedPhase 1DBV TechnologiesNCT03035370Written as Boostrix™
- Vaccine Responses in Infants After Acellular Pertussis Vaccination During Pregnancy in ThailandCompletedPhase 4Universiteit AntwerpenNCT02408926Written as Boostrix
- Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Meningococcal Vaccine With or Without Co-administration of Cervarix and Boostrix in Female Adolescents and Young AdultsCompletedPhase 3GlaxoSmithKlineNCT01755689Written as Boostrix®
- A Study of the Immune Response to Vaccines and Ixekizumab (LY2439821) in Healthy ParticipantsCompletedPhase 1Eli Lilly and CompanyNCT02543918Written as Boostrix®
As the comparator · 12 — what is tested is compared with Boostrix
- A Study to Learn About a COVID-19 Vaccine in Healthy Adults 18 Through 64 Years of AgeRecruitingPhase 4BioNTech SENCT07730450Written as Tdap Vaccine
- A Phase I/II Study to Evaluate the Safety and Immunogenicity of GC3111B in Healthy AdultsRecruitingPhase 1/2GC Biopharma CorpNCT06997627Written as Boostrix®
- A Study on the Safety and Immune Responses to the GVGH altSonflex1-2-3 Vaccine Against Shigellosis in Adults, Children, and InfantsCompletedPhase 1/2GlaxoSmithKlineNCT05073003Written as Boostrix
- A Study to Evaluate Safety, Reactogenicity, and Immune Response of GVGH iNTS-TCV Vaccine Against Invasive Nontyphoidal Salmonella and Typhoid FeverCompletedPhase 1/2GlaxoSmithKlineNCT05480800Written as GSK's Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine
- Safety and Immunogenicity of a Novel Conjugate Vaccine Against Salmonella Typhi and Salmonella Paratyphi A in Healthy AdultsCompletedPhase 1GlaxoSmithKlineNCT05613205Written as GSK's Tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine
- A Study to Evaluate the Safety and Efficacy(Immunogenicity) of GC3111 in Healthy AdultsStatus unknownPhase 2Green Cross CorporationNCT04238975Written as Boostrix® vaccine
- A Study of the Safety and Immune Response of 2 Doses of a New Shigella Vaccine in Kenyan AdultsCompletedPhase 2GlaxoSmithKlineNCT02676895Written as Boostrix
- Safety, Reactogenicity and Immunogenicity Study of Different Formulations of GlaxoSmithKline (GSK) Biologicals' Investigational RSV Vaccine (GSK3003891A), in Healthy WomenCompletedPhase 2GlaxoSmithKlineNCT02360475Written as Boostrix
- Safety and Reactogenicity Study of GlaxoSmithKline (GSK) Biologicals' Investigational Respiratory Syncytial Virus (RSV) Vaccine (GSK3003891A) in Healthy WomenCompletedPhase 2GlaxoSmithKlineNCT02753413Written as Boostrix
- Safety and Immunogenicity Study of Tetanus, Diphtheria and Acellular Pertussis (Tdap) VaccineStatus unknownPhase 1/2Green Cross CorporationNCT02813486Written as Biological: Boostrix® vaccine
- Persistency Study After aP / Tdap Booster Vaccines in Adult Subjects (V113_01 Extension 1)CompletedPhase 1NovartisNCT02382913Written as Licensed TdaP booster (Boostrix®)
- Immunogenicity of Adacel® and BOOSTRIX® Vaccines in AdolescentsCompletedPhase 4Sanofi Pasteur, a Sanofi CompanyNCT01629589Written as Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine, Adsorbed (BOOSTRIX®)
What changed recently
From the registry's own updates since Oct 17, 2026.